Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Exclusion Criteria

• •Central nervous system (CNS) metastases.
• •Chemotherapy or other anti-cancer therapy within 4 weeks prior to study day 1, and/or nitrosoureas within the 6 weeks prior to study day 1.
• •Lack of recovery from all toxic effects of previous chemotherapy, radiation therapy, biologic therapy, and/or experimental therapy with the exception of alopecia.
• •Radiation therapy within 4 weeks prior to study day 1.
• •Clinically significant pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal or genitourinary disease unrelated to underlying solid tumor or multiple myeloma
• •Significant cardiac risk (e.g. history of myocardial infarction, unstable angina, pulmonary hypertension, clinically significant arrhythmia, congestive heart failure within 1 year prior to study day 1).
• •Diagnosis or family history of hereditary hemorrhagic telangiectasia.
• •Major surgery within 6 weeks prior to study day 1.
• •Parenteral antibiotics, or any life-threatening or active infection requiring parenteral antibiotic therapy within 1 month prior to study day 1.
• •Therapeutic anti-coagulation.
• •Uncontrolled hypertension.
• •Autoimmune or hereditary hemolysis.
• •Clinically significant gastrointestinal bleeding or any other clinically significant active bleeding within 3 months prior to study day 1.
• •Treatment with another investigational drug or device, or approved therapy for investigational use within 28 days prior to study day 1.
• •Pregnancy or lactation for female patients.